经导管二尖瓣置换术治疗重度二尖瓣环钙化:SUMMIT-MAC研究主要结局
SUMMIT-MAC是首个评估Tendyne系统用于重度二尖瓣环钙化(MAC)的前瞻性临床试验。103例重度MAC伴显著二尖瓣功能障碍的高外科风险患者接受经导管二尖瓣置换术,12个月无全因死亡和心衰住院率为60.4%(性能目标43%,P=0.0002),心衰症状和生活质量显著改善。
要点
- 重度MAC高外科风险患者中,Tendyne经导管二尖瓣置换技术成功率达94.2%。
- 12个月无全因死亡和心衰住院率为60.4%,优于预设性能目标43%(P=0.0002)。
- NYHA I/II级比例从基线30.6%升至12个月87.5%,KCCQ评分平均提高18.7分。
核心结论
- 在重度MAC导致二尖瓣疾病的高外科风险患者中,Tendyne经导管二尖瓣置换术可实现成功治疗,并显著改善心衰症状和生活质量。
研究设计与样本
- SUMMIT-MAC是SUMMIT研究中的重度MAC队列,为首个评估Tendyne系统用于重度MAC的前瞻性临床试验。
- 共纳入103例重度MAC伴显著二尖瓣功能障碍且高外科风险的患者,平均年龄78.0±6.5岁,55%为女性。
- 超声核心实验室独立评估二尖瓣疾病,不良事件由独立临床事件委员会裁定。
- 主要终点为术后12个月无全因死亡和心衰住院。
主要发现
- 基线时97%的患者存在≥2+级二尖瓣反流。
- 技术成功率为94.2%,30天死亡率为6.8%。
- 12个月无全因死亡和心衰住院率为60.4%(性能目标43%,P=0.0002)。
- NYHA功能I/II级患者比例从基线30.6%升至12个月87.5%(P<0.0001)。
- KCCQ总体摘要评分平均配对增加18.7±24.4分(P<0.0001)。
临床怎么用
- 对于重度MAC伴显著二尖瓣功能障碍且高外科风险的症状性患者,Tendyne经导管二尖瓣置换术可作为改善心衰症状和生活质量的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Severe mitral annular calcification (MAC) carries significant risk. Safe and effective transcatheter options are needed for patients with MAC. OBJECTIVES: The goal of this study was to evaluate the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System (Abbott Structural Heart) in symptomatic patients with mitral disease due to severe MAC. METHODS: This analysis reports results from the severe MAC cohort of the SUMMIT (Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation) study, which was the first prospective clinical trial designed to assess the use of the Tendyne system for severe MAC. All patients had severe MAC with significant mitral valve dysfunction and were at high surgical risk. An echocardiography core laboratory performed independent assessments of mitral disease. Adverse events were adjudicated by an independent clinical events committee. The primary endpoint was freedom from all-cause mortality and heart failure hospitalization at 12 months' postindex procedure. RESULTS: Overall, 103 patients (mean age 78.0 ± 6.5 years; 55% female) with severe MAC and mitral regurgitation or stenosis underwent treatment with Tendyne. Mitral regurgitation was present in nearly all patients at baseline (ie, 97% of patients with grade ≥2+). Technical success was achieved in 94.2%, with a 30-day mortality of 6.8%. The primary endpoint was met: freedom from all-cause mortality and heart failure hospitalization was 60.4% at 12 months (performance goal: 43%; P = 0.0002). Heart failure symptoms improved significantly (NYHA functional class I/II: 30.6% vs 87.5% [paired baseline vs 12 months]; P < 0.0001) and quality of life improved significantly (mean paired increase in the Kansas City Cardiomyopathy Questionnaire Overall Summary: 18.7 ± 24.4 points; P < 0.0001). CONCLUSIONS: In this first report of the primary outcomes of the SUMMIT-MAC clinical trial, transcatheter mitral valve replacement with Tendyne led to successful treatment of mitral valve disease due to MAC and significant improvements in heart failure symptoms and quality of life.
引用
- Sorajja P, Thourani VH, Rogers JH, et al. Transcatheter Mitral Valve Replacement for Severe Mitral Annular Calcification: Primary Outcomes From the SUMMIT-MAC Study. J Am Coll Cardiol. 2025. PMID: 41194751. doi:10.1016/j.jacc.2025.10.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。